Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Green, J. B.
Right arrow Articles by Freed, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Green, J. B.
Right arrow Articles by Freed, D. M.

Neurology, Vol 45, Issue 5 962-966, Copyright © 1995 by American Academy of Neurology

ARTICLES

The P1 component of the middle latency auditory evoked potential predicts a practice effect during clinical trials in Alzheimer's disease

JB Green, WW Elder and DM Freed
Texas Tech University Health Sciences Center, Department of Neurology, Lubbock, TX, USA.

Thirty-five patients with probable Alzheimer's disease who were enrolled in an experimental drug trial of linopirdine underwent repeated testing that included recording the middle latency auditory evoked potential (MLAEP), the Mini-Mental State Examination (MMSE), and the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADASCOG). Patients lacking the P1 component of the MLAEP exhibited a significantly greater decline in cognitive function as measured by the ADASCOG over 56 weeks. This decline appeared to be due to a less robust practice effect, which was maximal in all patients at 16 weeks. At the end of 56 weeks the entire group of patients was near baseline with respect to the ADASCOG. This lack of the annualized decline expected from other longitudinal studies may be explained by practice and placebo effects. The MMSE did not exhibit a practice effect and showed the expected decline in scores.


This article has been cited by other articles:


Home page
 J Geriatr Psychiatry NeurolHome page
L. Demers, M. Oremus, A. Perrault, and C. Wolfson
Review of Outcome Measurement Instruments in Alzheimer's Disease Drug Trials: Introduction
J Geriatr Psychiatry Neurol, December 1, 2000; 13(4): 161 - 168.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by AAN Enterprises, Inc.